Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant
Autor: | Robert Puckrin, Neil Chua, Mona Shafey, Douglas A. Stewart |
---|---|
Rok vydání: | 2022 |
Předmět: |
Adult
Cancer Research Hematopoietic Stem Cell Transplantation Neoplasms Second Primary Hematology Middle Aged Combined Modality Therapy Transplantation Autologous Central Nervous System Neoplasms Young Adult Methotrexate Treatment Outcome Oncology Antineoplastic Combined Chemotherapy Protocols Humans Lymphoma Large B-Cell Diffuse Autografts Rituximab Busulfan Cyclophosphamide Melphalan Thiotepa Aged Retrospective Studies |
Zdroj: | Leukemialymphoma. 63(10) |
ISSN: | 1029-2403 |
Popis: | Secondary central nervous system lymphoma (SCNSL) affects approximately 5% of patients with aggressive large B-cell lymphoma (LBCL) and is associated with poor outcomes. This retrospective, multicenter study included 62 consecutive patients with SCNSL intended for transplant with high-dose methotrexate (HD-MTX)-based induction followed by high-dose thiotepa, busulfan, melphalan, rituximab (TBMR) conditioning and autologous stem cell transplantation (ASCT). Median age was 58 years (range 20-75) and 52 (84%) patients had ECOG performance statusgt;1 at diagnosis of SCNSL. Fifty-two (84%) patients completed induction and proceeded to TBMR/ASCT. With median follow-up 5.7 years, 5-year progression-free and overall survival rates were 53% (95% CI 39-65%) and 65% (95% CI 51-76%) for all patients and 62% (95% CI 45-74%) and 73% (95% CI 57-84%) for those undergoing TBMR/ASCT, respectively. Despite a historically poor prognosis, HD-MTX-based induction followed by TBMR/ASCT has the potential to achieve long-term survival in a substantial proportion of patients with SCNSL. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |